In fact, angiotensin-converting enzyme inhibitors and AT1-R blockers have been reported to improve liver fibrosis scores clinically [43], suggesting that the AGTR1-mediated pathway is involved in HSC activation. The gene discussed is ACE; the disease is Hepatic fibrosis.